SCHEMBL1908507

SCHEMBL1908507

CC(C)(CO)c1cccc(CN)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.47
KIF11 P52732 2/20 0.45
NOS1 P29475 5/20 0.43
NOS2 P35228 5/20 0.43
PNMT P11086 1/20 0.42
NOS3 P29474 3/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP3A4 P08684 1/20 0.42
NFKB1 P19838 1/20 0.42
LOXL2 Q9Y4K0 3/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
TAAR1 Q96RJ0 2/20 0.41
MAOB P27338 1/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30288253 0.86 TAAR1 (0.59) KIF11NOS1SMN1; SMN2CYP3A4NFKB1
SCHEMBL1908555 0.85 KIF11 (0.44) KIF11CYP1A2CYP2C19TAAR1CNR1
SCHEMBL15045357 0.82 CNR1 (0.47) ALDH1A1SMN1; SMN2CYP3A4CYP1A2CYP2C19
SCHEMBL15504962 0.81 MEN1 (0.40) KIF11ALDH1A1CYP1A2CYP2C19TAAR1
SCHEMBL1908518 0.81 ENPP2 (0.50) ENPP2KIF11NOS1NOS2PNMT
SCHEMBL507652 0.80 KIF11 (0.50) ENPP2KIF11NOS1NOS2PNMT
SCHEMBL29755008 0.80 KIF11 (0.50) ENPP2KIF11NOS1NOS2PNMT
SCHEMBL19754735 0.80 ESR1 (0.45) KIF11NOS1NOS2NOS3LOXL2
SCHEMBL27317288 0.79 ENPP2 (0.48) ENPP2KIF11NOS1NOS2PNMT
SCHEMBL8090388 0.79 KIF11 (0.43) ENPP2KIF11NOS1NOS2PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093406-B2 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2012-01-10 US disclosed
US-8093406-B2 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2012-01-10 US disclosed
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2010-03-04 US disclosed
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2010-03-04 US disclosed
WO-2010003976-A1 CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2010-01-14 WO disclosed
WO-2009024615-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2009-02-26 WO disclosed
US-20090054427-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS BRIARD EMMANUELLE 2009-02-26 US disclosed
US-20090054427-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS BRIARD EMMANUELLE 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054427-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS BACE2, BACE1, APP ENPP2 1028/4885KIF11 4597/4885NOS1 1187/4885
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors BACE2, BACE1, APP ENPP2 1482/4885KIF11 4412/4885NOS1 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.